Ajanta Pharma Ltd vs Shilpa Medicare Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Ajanta Pharma Ltd is ₹ 2824 as of 30 Apr 15:30 . The P/E Ratio of Ajanta Pharma Ltd changed from 23.9 on March 2021 to 35.7 on March 2025 . This represents a CAGR of 8.36% over 5 yearsThe P/E Ratio of Shilpa Medicare Ltd changed from 18.4 on March 2021 to 82.8 on March 2025 . This represents a CAGR of 35.10% over 5 years The Market Cap of Ajanta Pharma Ltd changed from ₹ 15517 crore on March 2021 to ₹ 32708 crore on March 2025 . This represents a CAGR of 16.08% over 5 yearsThe Market Cap of Shilpa Medicare Ltd changed from ₹ 2721 crore on March 2021 to ₹ 6483 crore on March 2025 . This represents a CAGR of 18.96% over 5 years The revenue of Ajanta Pharma Ltd for the Dec '25 is ₹ 1399 crore as compare to the Sep '25 revenue of ₹ 1413 crore. This represent the decline of -0.94% The revenue of Shilpa Medicare Ltd for the Dec '25 is ₹ 410.54 crore as compare to the Sep '25 revenue of ₹ 371.72 crore. This represent the growth of 10.44% The ebitda of Ajanta Pharma Ltd for the Dec '25 is ₹ 407.21 crore as compare to the Sep '25 ebitda of ₹ 387.17 crore. This represent the growth of 5.18% The ebitda of Shilpa Medicare Ltd for the Dec '25 is ₹ 101.9 crore as compare to the Sep '25 ebitda of ₹ 109.92 crore. This represent the decline of -7.3% The net profit of Ajanta Pharma Ltd changed from ₹ 245.77 crore to ₹ 273.77 crore over 7 quarters. This represents a CAGR of 6.36% The net profit of Shilpa Medicare Ltd changed from ₹ 14.06 crore to ₹ 44.58 crore over 7 quarters. This represents a CAGR of 93.36% The Dividend Payout of Ajanta Pharma Ltd changed from 12.23 % on March 2021 to 38.28 % on March 2025 . This represents a CAGR of 25.63% over 5 yearsThe Dividend Payout of Shilpa Medicare Ltd changed from 4.86 % on March 2021 to 14.01 % on March 2025 . This represents a CAGR of 23.58% over 5 years .

About Ajanta Pharma Ltd

Ajanta Pharma Limited is a specialty pharmaceutical formulation company primarily with a well-diversified Branded Generics business spread across India, the Rest of Asia, and Africa.
The Company is involved in development, manufacturing and marketing of quality finished dosages in domestic and international markets.
It produces a comprehensive range of specialty products targeting different therapeutic segments.
It has strong chronic-focused product portfolio led by a first-to-market strategy and front-end presence which helps it outgrow the market. The company's business includes Branded Generics in emerging markets of Asia and Africa, Generics in the developed markets of USA and Institution sales.
The branded generics business is spread in India and more than 30 emerging countries across Africa, CIS, the Middle East and South East Asia.

About Shilpa Medicare Ltd

Shilpa Medicare Limited, formerly known as Shilpa Antibiotics Private Limited was incorporated as a Private Company on November 20, 1987.
The Company changed the status to Public and the name of the Company changed to Shilpa Antibiotics Limited in November, 1993 and later on, was changed to 'Shilpa Medicare Limited' on February 17, 2003. The Company has been promoted by Vishnukant C. Bhutada and his Associates and is engaged in manufacturing of API, Formulation and Development service.
The Company started its operations as API manufacturer way back in 1987 at Raichur, Karnataka.
It then started commercial production in November, 1989. The Company is one of the leading API and formulations manufacturers with strong capabilities in the therapeutic area of oncology.
It supplies more than 30 oncology APIs including key products such as Capecitabine, Gemcitabine Hydrochloride, Axitinib, Erlotinib Hydrochloride and Irinotecan Hydrochloride for various regulated markets including USA, Europe, Japan, South Korea, Russia, Mexico, Brazil, and other emerging markets.

FAQs for the comparison of Ajanta Pharma Ltd and Shilpa Medicare Ltd

Which company has a larger market capitalization, Ajanta Pharma Ltd or Shilpa Medicare Ltd?

Market cap of Ajanta Pharma Ltd is 35,289 Cr while Market cap of Shilpa Medicare Ltd is 7,958 Cr

What are the key factors driving the stock performance of Ajanta Pharma Ltd and Shilpa Medicare Ltd?

The stock performance of Ajanta Pharma Ltd and Shilpa Medicare Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Ajanta Pharma Ltd and Shilpa Medicare Ltd?

As of May 4, 2026, the Ajanta Pharma Ltd stock price is INR ₹2824.6. On the other hand, Shilpa Medicare Ltd stock price is INR ₹406.9.

How do dividend payouts of Ajanta Pharma Ltd and Shilpa Medicare Ltd compare?

To compare the dividend payouts of Ajanta Pharma Ltd and Shilpa Medicare Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.